Advantest Corp (ATE)

12.61
0.53 4.37
OTC : Technology
Prev Close 12.08
Open 12.60
Day Low/High 12.59 / 12.62
52 Wk Low/High 7.01 / 12.08
Volume 4.21K
Avg Volume 20.40K
Exchange OTC
Shares Outstanding 174.57M
Market Cap 1.71B
EPS 0.62
P/E Ratio N/A
Div & Yield 0.16 (1.70%)

Latest News

IIROC Trading Resumption - ATE

IIROC Trading Resumption - ATE

IIROC Trading Halt - ATE

IIROC Trading Halt - ATE

Antibe Therapeutics Engages MKR Group For U.S. Investor Relations

Antibe Therapeutics Engages MKR Group For U.S. Investor Relations

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQX: ATBPF) today announced that it has retained MKR Group, Inc.

Antibe Therapeutics Announces The Launch Of PentOS OI™ Max, Its Newest Bone Graft Substitute For Oral And Maxillofacial Surgery

Antibe Therapeutics Announces The Launch Of PentOS OI™ Max, Its Newest Bone Graft Substitute For Oral And Maxillofacial Surgery

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) today announced that its subsidiary Citagenix Inc.

Antibe Therapeutics Announces Change Of Auditor To Ernst & Young

Antibe Therapeutics Announces Change Of Auditor To Ernst & Young

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQX: ATBPF) announced today that its board of directors (the "Board") has approved a change of the Company's auditor.

Antibe Therapeutics Raises $2.4 Million In First Tranche Of Private Placement

Antibe Therapeutics Raises $2.4 Million In First Tranche Of Private Placement

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") (TSXV:ATE, OTCQX:ATBPF) is pleased to announce the successful completion of the first tranche of a private placement of units consisting of brokered and non-brokered...

Antibe Therapeutics Reports Q2 2017 Interim Financial And Operating Results

Antibe Therapeutics Reports Q2 2017 Interim Financial And Operating Results

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE) (OTCQX:ATBPF) filed its financial and operating results on Tuesday, November 29 for the fiscal quarter ended September 30, 2016.

Antibe Therapeutics Confirms Non-Addictive Properties For Its Second Pipeline Drug, ATB-352, A Potent, Non-Addictive Pain-Killer

Antibe Therapeutics Confirms Non-Addictive Properties For Its Second Pipeline Drug, ATB-352, A Potent, Non-Addictive Pain-Killer

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) is pleased to provide an update on it second pipeline drug, ATB-352, a potent pain-killer intended for the relief of acute, severe pain.

Antibe Therapeutics Announces Payment In Kind Election

Antibe Therapeutics Announces Payment In Kind Election

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) announces it has elected to pay in kind all interest due October 15, 2016 under the Company's 10% senior secured convertible debentures due October 15, 2018 (the...

Antibe Therapeutics Announces Launch Of Strategic Growth Initiative In The U.S. Market For Dental Biologics

Antibe Therapeutics Announces Launch Of Strategic Growth Initiative In The U.S. Market For Dental Biologics

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF), a commercial-stage pharmaceutical growth company, today announces that its subsidiary Citagenix Inc.

Antibe Therapeutics To Present At 2016 Rodman & Renshaw Global Investment Conference

Antibe Therapeutics To Present At 2016 Rodman & Renshaw Global Investment Conference

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF), a commercial-stage pharmaceutical growth company, today announced that it will be presenting at the 18th Annual Rodman & Renshaw Global Investment...

Antibe Therapeutics Announces The Launch Of Neomem® FlexPlus, A High-Performance Barrier Membrane For Oral Surgery

Antibe Therapeutics Announces The Launch Of Neomem® FlexPlus, A High-Performance Barrier Membrane For Oral Surgery

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) today announces that its subsidiary Citagenix Inc.

Antibe Therapeutics Announces Successful Phase 2 Trial Of ATB-346 In Osteoarthritis

Antibe Therapeutics Announces Successful Phase 2 Trial Of ATB-346 In Osteoarthritis

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE; OTCQX: ATBPF) is pleased to announce the successful completion of its phase 2 clinical trial of ATB-346 in osteoarthritis ("OA").

Antibe Therapeutics Reports 2016 Year-End Financial And Operating Results

Antibe Therapeutics Reports 2016 Year-End Financial And Operating Results

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) filed its financial and operating results Friday, July 29 for the fourth quarter and the year ended March 31, 2016.

Antibe Therapeutics Announces The Appointment Of New Board Member And Provides Update On Phase 2 Trial Of ATB-346

Antibe Therapeutics Announces The Appointment Of New Board Member And Provides Update On Phase 2 Trial Of ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") (TSXV:ATE, OTCQX:ATBPF), a commercial-stage pharmaceutical growth company, is pleased to announce the appointment of Yung Wu to its Board of Directors.

Antibe Therapeutics Presenting Update On ATB-346 At International Hydrogen Sulfide Conference

Antibe Therapeutics Presenting Update On ATB-346 At International Hydrogen Sulfide Conference

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) will be front-and-centre at the 4 th International Conference on the Biology of Hydrogen Sulfide, to be held in Naples, Italy from June 3 rd to 5th.

Advantest Earns 28th Consecutive Ranking As A 10 BEST Supplier Of Semiconductor Test Equipment, Excelling As Global Customers Rate System Uptime As Paramount In The Industry

Advantest Earns 28th Consecutive Ranking As A 10 BEST Supplier Of Semiconductor Test Equipment, Excelling As Global Customers Rate System Uptime As Paramount In The Industry

For the 28 th consecutive year, leading semiconductor test equipment supplier, Advantest Corporation (TSE:6857), has been named a distinguished 10 BEST Supplier of Chip Making Equipment in the annual VLSIresearch Customer...

Antibe Therapeutics To Present At 2016 Bloom Burton & Co. Healthcare Investor Conference

Antibe Therapeutics To Present At 2016 Bloom Burton & Co. Healthcare Investor Conference

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF), a commercial-stage pharmaceutical growth company, is pleased to announce that CEO Daniel Legault will be presenting at the fifth annual Bloom Burton & Co.

Antibe Therapeutics Announces The Launch Of PentOS OI™ Putty, A High-Quality Bone Graft Substitute For Oral And Maxillofacial Surgery

Antibe Therapeutics Announces The Launch Of PentOS OI™ Putty, A High-Quality Bone Graft Substitute For Oral And Maxillofacial Surgery

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) today announced that its subsidiary Citagenix Inc.

Antibe Therapeutics Announces Appointment Of The Giordano Group, Inc, A Division Of Network 1 Financial Securities LLC, As US-BASED Investor Relations Consultant

Antibe Therapeutics Announces Appointment Of The Giordano Group, Inc, A Division Of Network 1 Financial Securities LLC, As US-BASED Investor Relations Consultant

Antibe Therapeutics Inc ("Antibe" or the "Company") (TSXV:ATE, OTCQX:ATBPF) has retained the Giordano Group, Inc ("Giordano Group"), a division of Network 1 Financial Securities LLC ("Network 1"), to provide investor...

Antibe Therapeutics Announces Grant Of Stock Options

Antibe Therapeutics Announces Grant Of Stock Options

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) announces that it has granted its directors, officers and employees options to purchase a total of 6,751,000 common shares of Antibe pursuant to the...

Antibe Therapeutics' ATB-346 Receives Approval For Phase 2 Clinical Trial In Osteoarthritis Patients

Antibe Therapeutics' ATB-346 Receives Approval For Phase 2 Clinical Trial In Osteoarthritis Patients

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) has received approval from Health Canada to conduct a Phase 2 trial of its lead drug, ATB-346, in patients with osteoarthritis of the knee.

Antibe Therapeutics Receives Approval To Proceed To Phase 2 Clinical Trial

Antibe Therapeutics Receives Approval To Proceed To Phase 2 Clinical Trial

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) is pleased to announce that it has received approval from Health Canada to initiate a Phase 2 trial.

Antibe Therapeutics Reports Q3 2016 Interim Financial And Operating Results

Antibe Therapeutics Reports Q3 2016 Interim Financial And Operating Results

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) filed its financial and operating results Monday, February 29 for the fiscal quarter ended December 31, 2015.

Profound Preventative And Restorative Effects Of ATB-346 In Mice With Genetic Predisposition To Intestinal Cancer

Profound Preventative And Restorative Effects Of ATB-346 In Mice With Genetic Predisposition To Intestinal Cancer

In an article published today in the journal PLOS ONE, an international team of scientists led by Antibe Therapeutics Inc.

W2BI, Inc. To Demonstrate New Automated Mobile Device Test System For IoT Applications, Along With Smart Device Production Test Systems At Mobile World Congress In Barcelona, February 22-25, 2016

W2BI, Inc. To Demonstrate New Automated Mobile Device Test System For IoT Applications, Along With Smart Device Production Test Systems At Mobile World Congress In Barcelona, February 22-25, 2016

W2BI, Inc., a member of the Advantest Group (NYSE:ATE), and a leading software provider of wireless device test automation products for the world's top mobile operators and suppliers, announced that it will participate in...

W2BI Demonstrates New Automated Mobile Device Test System For Internet-of-Things Devices, And Its Newest Smart Device Production Test Systems At Mobile World Congress In Barcelona, February 22-25, 2016

W2BI Demonstrates New Automated Mobile Device Test System For Internet-of-Things Devices, And Its Newest Smart Device Production Test Systems At Mobile World Congress In Barcelona, February 22-25, 2016

W2BI, Inc., a member of the Advantest Group (NYSE:ATE), and a leading software provider of wireless device test automation products for the world's top mobile operators and suppliers, announced that it will again exhibit at...

Antibe Therapeutics Closes Acquisition Of Minority Interest In Citagenix Inc.

Antibe Therapeutics Closes Acquisition Of Minority Interest In Citagenix Inc.

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE, OTCQX:ATBPF) announces that it has completed the acquisition of the remainder 15% minority interest in Citagenix Inc.